Aktis Oncology to Present at Upcoming March Investor Conferences
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $34.00 price target on the stock.